目的 探討金振口服液聯(lián)合哌拉西林鈉他唑巴坦鈉治療兒童社區(qū)獲得性肺炎的臨床療效。方法 選取2022年1月—2024年11月在中山市小欖人民醫(yī)院接受治療的86例社區(qū)獲得性肺炎患兒，按隨機數(shù)字表法將患兒分為對照組和治療組，每組各43例。對照組患兒采用注射用哌拉西林鈉他唑巴坦鈉，2.25 g/次，用稀釋液充分溶解后加入100 mL注射液中靜脈滴注，≥30 min/次，3次/d。治療組在對照組治療基礎(chǔ)上口服金振口服液，5 mL/次，3次/d。兩組療程均為7 d。觀察兩組臨床療效和相關(guān)癥狀改善時間，比較治療前后血氣指標(biāo)[動脈血氧分壓（pO₂）、動脈血二氧化碳分壓（pCO₂）]和炎癥標(biāo)志物[C反應(yīng)蛋白（CRP）、中性粒細胞與淋巴細胞比值（NLR）、嗜酸性粒細胞（EOS）計數(shù)、血清降鈣素原（PCT）]水平。結(jié)果 治療后，治療組總有效率是97.67%，顯著高于對照組的86.05%（P＜0.05）。治療后，治療組喘促、咳嗽、發(fā)熱、痰鳴、肺部啰音的改善時間均顯著短于對照組（P＜0.05）。治療后，兩組pO₂顯著升高，而pCO₂均顯著降低（P＜0.05）；治療后，治療組pO₂高于對照組，pCO₂低于對照組（P＜0.05）。治療后，兩組CRP、NLR、EOS計數(shù)和血清PCT水平都低于組內(nèi)治療前（P＜0.05）；治療組CRP、NLR、EOS計數(shù)和血清PCT水平都低于對照組（P＜0.05）。結(jié)論 兒童社區(qū)獲得性肺炎應(yīng)用金振口服液聯(lián)合哌拉西林鈉他唑巴坦鈉治療，療效顯著，安全性良好。該聯(lián)合療法能有效緩解癥狀，改善血氣指標(biāo)，減輕炎癥反應(yīng)，為兒童社區(qū)獲得性肺炎的治療提供了較佳選擇。

Objective To investigate the clinical efficacy of Jinzhen Oral Liquid combined with piperacillin sodium and tazobactam sodium in treatment of community-acquired pneumonia in children. Methods A total of 86 children with community-acquired pneumonia who were treated in Xiaolan People’s Hospital of Zhongshan from January 2022 to November 2024 were selected and divided into control group and treatment group according to random number table method, with 43 cases in each group. The children in control group were treated with piperacillin sodium and tazobactam sodium for injection, 2.25 g each time. After being fully dissolved in the diluent, it was added to 100 mL of the injection solution for intravenous drip infusion, ≥ 30 minutes each time, 3 times daily. The children in treatment group took Jinzhen Oral Liquid orally on the basis of control group, 5 mL each time, 3 times daily. The treatment courses of both groups were 7 d. The clinical efficacy and improvement time of related symptoms were observed. The blood gas indexes [arterial partial pressure of oxygen (pO₂), arterial partial pressure of carbon dioxide (pCO₂)] and inflammatory markers [C-reactive protein (CRP), neutrophil lymphocyte ratio (NLR), eosinophil (EOS) count and serum procalcitonin (PCT)] levels before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 97.67%, significantly higher than that of control group (86.05%, P < 0.05). After the treatment, the improvement times of shortness of breath, cough, fever, phlegm rumbling, and pulmonary rales in treatment group were significantly shorter than those in control group (P < 0.05). After treatment, pO₂ in both groups increased significantly, but pCO₂ decreased significantly (P < 0.05). After treatment, the pO₂ in the treatment group was higher than that in control group, and the pCO₂ was lower than that in control group (P < 0.05). After treatment, the level of CRP, NLR, EOS, and serum PCT in both groups were lower than those before treatment within the same groups (P < 0.05). The level of CRP, NLR, EOS, and serum PCT in treatment group were all lower than those in control group (P < 0.05). Conclusion Jinzhen Oral Liquid combined with piperacillin sodium and tazobactam sodium is effective and safe in treatment of community-acquired pneumonia in children. The combination therapy can effectively relieve symptoms, improve blood gas indexes, reduce inflammatory reaction, and provide a better choice for the treatment of community-acquired pneumonia in children.

R974